Explore the latest insights, updates, and breakthroughs in cryopreservation and Pentahibe innovation.
Research shows that reducing DMSO from 10% to 5% dramatically lowers infusion-related adverse events—without affecting engraftment. At Pentahibe, this is our mission: safe and efficient cryopreservation with no compromise.
Pharmacosmos and InVitria introduce an animal-origin-free cryopreservation strategy for T cells, combining Pentahibe® Base and Optibumin® 25 to deliver strong results with just 2% DMSO.
Can organoid success start with cryopreservation?Discover how Pentahibe Complete enabled 100% organoid establishment from preserved biopsies, in collaboration with the Cambridge Stem Cell Institute.
Is it time to move beyond DMSO?Discover how Pharmacosmos is shaping the future of safe, efficient cryopreservation with Pentahibe — a next-gen, biocompatible solution for cells, tissues, and organoids.
Visit our Data & Documents page to learn more.